Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA

Journal of Infectious Diseases

Volumn 182, Issue 6, 2000, Pages 1694-1701

  Vernazza, Pietro L ^a   Kahlert, Christian ^a   Fierz, Walter ^a  

^a Institute for Clinical Immunology and Microbiology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; PNEUMOCOCCUS SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED CBA; PNEUMOCOCCAL INFECTIONS; RATS; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0033680686     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317602     Document Type: Article

References (45)

1. Pneumococcal polysaccharide immunization in infants and children
2. Protective efficacy of polyvalent pneumococcal polysaccharide vaccine
3. Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers
4. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
5. Clinical and epidemiologic studies of pneumococcal infection in children
6. Which pneumococcal serogroups cause the most invasive disease implications for conjugate vaccine formulation and use, part 1
7. The contribution of specific pneumococcal serogroups to different disease manifestations. II. Implications for conjugate vaccine formulation and use
8. Strategies for the control of pneumococcal diseases
9. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations
10. Vaccine strategies for Streptococcus pneumoniae
11. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
12. Immunity to Streptococcus pneumoniae
13. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies
14. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae
15. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by binding of complement regulatory protein factor H
16. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae
17. Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae
18. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis
19. Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae
20. Novel surface attachment mechanism for the Streptococcus pneumoniae protein PspA
21. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice
22. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types
23. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type
24. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260
25. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae
26. Human antibodies to pneumococcal surface protein A, PspA
27. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B
28. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic
29. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III
30. Differences in virulence of mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production
31. A strong association between capsular type and mouse virulence among human isolates of Streptococcus pneumoniae
32. Virulence of Streptococcus pneumoniae in mice: A standardized method for preparation and frozen storage of the experimental bacterial inoculum
33. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens
34. Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia
35. Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae
36. PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice
37. Molecular localization of variable and conserved regions of pspA, and identification of additional pspA homologous sequences in Streptococcus pneumoniae
38. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae
39. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae
40. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins
41. Pneumococcal diversity: Considerations for new vaccine strategies with an emphasis on pneumococcal surface protein A (PspA)
42. B-lymphocyte activation